Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo : rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker
Open Access
- 1 January 2003
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 2 (1) , 5
- https://doi.org/10.1186/1475-2875-2-5
Abstract
Resistance of Plasmodium falciparum to atovaquone in vitro and in vivo has been associated to mutations in the parasite cytochrome b gene. Cultures were sequentially subjected to increasing doses of atovaquone alone or in combination with cycloguanil and the cytochrome b gene was sequenced. Additionally, we investigated the parasite cytochrome b gene of a patient returning from Mali with Malarone® treatment failure in vivo. All strains that survived atovaquone concentrations in vitro of 2 × 10-8 to 2 × 107 M showed the M133I mutation and one strain with the highest atovaquone concentration the additional mutation L171F. Sequencing of the in vivo treatment failure revealed a point mutation at codon 268 resulting in an amino acid change from tyrosine to serine. Based on the repeated emergence of mutations at codon 268, but no detection of alterations at codon 133 in vivo, we developed a detection method for the diagnostic of codon 268 polymorphisms as a potential atovaquone/proguanil resistance marker. A nested PCR with 3 different pairs of primers for the second round was designed. Each product was digested with restriction enzymes, capable to distinguish the wild type from the two reported mutations at codon 268. Mutations at codon 268 of the parasite cytochrome bc1 gene are associated with atovaquone/proguanil treatment failure in vivo and can be used as potential resistance marker This method provides a novel and robust tool to investigate the relevance of codon 268 polymorphisms as resistance marker and to monitor the further emergence of atovaquone/proguanil resistance.This publication has 21 references indexed in Scilit:
- Mutations in Cytochrome b Resulting in Atovaquone Resistance Are Associated with Loss of Fitness in Plasmodium falciparumAntimicrobial Agents and Chemotherapy, 2002
- Molecular surveillance of drug resistance through imported isolates of Plasmodium falciparum in EuropeMalaria Journal, 2002
- Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfadoxine for treatment of acute Plasmodium falciparum malaria in PeruThe Brazilian Journal of Infectious Diseases, 2001
- Atovaquone‐Proguanil Compared with Chloroquine and Chloroquine‐Sulfadoxine‐Pyrimethamine for Treatment of AcutePlasmodium falciparumMalaria in the PhilippinesThe Journal of Infectious Diseases, 1999
- Sequence Polymorphisms in thePneumocystis cariniiCytochromebGene and Their Association with Atovaquone Prophylaxis FailureThe Journal of Infectious Diseases, 1998
- Atovaquone, a Broad Spectrum Antiparasitic Drug, Collapses Mitochondrial Membrane Potential in a Malarial ParasiteJournal of Biological Chemistry, 1997
- Atovaquone and proguanil for Plasmodium falciparum malariaThe Lancet, 1996
- Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinonesMolecular and Biochemical Parasitology, 1993
- Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80)Biochemical Pharmacology, 1992
- Human Malaria Parasites in Continuous CultureScience, 1976